Gyrolab®: Case Studies in Assay Development and Validation

Now Streaming On-Demand

In association with Bioanalysis Zone, BioAgilytix would like to present Gyrolab, a platform that provides a highly automated platform that optimizes immunoassays for use at the nanoliter-scale, enabling testing when sample volume is limited. As part of this webinar, we will talk about BioAgilytix’s experience with this platform as it relates to assay development and validation in the context of both regulated and non-regulated support.

During the webinar, you will learn:

Experience with:

  • Different matrices and species
  • Troubleshooting tips
  • Regulated vs. non-regulated support
  • Logistics issues (sample volume, CDs, buffers)

WHO MAY THIS INTEREST?

  • Bioanalytical scientists
  • Biomarker scientists
  • Those working in non-clinical development (pharmacology and toxicology)

ABOUT THE PRESENTERS

Dr. Jim McNally has an extensive background in bioanalytical assay development and program leadership spanning 20+ years working in the pharmaceutical and biotechnology industry. Prior to joining BioAgilytix, Dr McNally was Executive Director at CRISPR Therapeutics (MA, USA), where he led a team of scientists to develop assays to support development of gene-edited therapeutic candidates. He has also previously held roles at Genzyme (MA, USA), Pfizer (MA, USA), EMD Serono (MA, USA) and Shire (MA, USA), which have given him broad experience in the development of large molecule, gene therapy and cell therapy biotherapeutics. He has a special interest in the immunogenicity of biotherapeutics and leads an industry-wide working group on this topic.

Carla Mejia has over 13 years of experience in the pharmaceutical industry, including over 8 years at BioAgilytix. Before joining the BAL team, Carla worked for GSK (NC, USA) and Grifols (NC, USA). She has over a decade of experience working on development, validation and sample analysis of immunogenicity ELISA and PK assays. She has extensive experience developing assays for a variety of matrices for both animal and human studies. At BioAgilytix, Carla currently manages an FTE model team that develops, validates and executes sample analysis for PK, ADA and biomarker assays on multiple platforms including MSD, ELISA and Gyros platforms. She earned her Bachelor of Science in Biochemistry from North Carolina State University (NC, USA).

Cell-Based Assays

Learn how BioAgilytix provides the specialized large molecule insight and proven GLP / GMP knowledge needed to support a full range of cell-based assay (CBA) requirements.

Pharmacokinetics & Pharmacodynamics (PK/PD)

See how our PK expertise complements our immunogenicity services by evaluating absorption, distribution, metabolism and excretion characteristics of a product.

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Tell Us About Your Project

What are your specific assay needs? Let’s schedule a conversation to review your
questions and requirements with one of our scientists.

SPEAK TO A SCIENTIST

Cell-Based Assays

Learn how BioAgilytix provides the specialized large molecule insight and proven GLP / GMP knowledge needed to support a full range of cell-based assay (CBA) requirements.

Pharmacokinetics & Pharmacodynamics (PK/PD)

See how our PK expertise complements our immunogenicity services by evaluating absorption, distribution, metabolism and excretion characteristics of a product.

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Tell Us About Your Project

What are your specific assay needs? Let’s schedule a conversation to review your
questions and requirements with one of our scientists.

SPEAK TO A SCIENTIST
Share This